| Year |
Citation |
Score |
| 2023 |
Radoiu C, Govindarajan B, Wang M, Sbrissa D, Cher ML, Chinni SR. A Novel Interaction between Chemokine and Phosphoinositide Signaling in Metastatic Prostate Cancer. Medical Research Archives. 11. PMID 38239314 DOI: 10.18103/mra.v11i7.1.4020 |
0.532 |
|
| 2023 |
Govindarajan B, Sbrissa D, Pressprich M, Kim S, Rishi AK, Vaishampayan U, Cher ML, Chinni SR. Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth. Scientific Reports. 13: 20634. PMID 37996444 DOI: 10.1038/s41598-023-47633-4 |
0.549 |
|
| 2023 |
Govindarajan B, Sbrissa D, Pressprich M, Kim S, Vaishampayan U, Cher ML, Chinni S. Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth. Research Square. PMID 36865146 DOI: 10.21203/rs.3.rs-2590830/v1 |
0.549 |
|
| 2021 |
Mazzu YZ, Liao Y, Nandakumar S, Sjöström M, Jehane LE, Ghale R, Govindarajan B, Gerke TA, Lee GM, Luo JH, Chinni SR, Mucci LA, Feng FY, Kantoff PW. Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity. Molecular Oncology. PMID 34792282 DOI: 10.1002/1878-0261.13140 |
0.586 |
|
| 2021 |
Chinni SR. Novel lipid mediators contributing to androgen receptor therapy resistance in prostate cancer. Ebiomedicine. 74: 103696. PMID 34775352 DOI: 10.1016/j.ebiom.2021.103696 |
0.488 |
|
| 2021 |
Vaishampayan UN, Heilbrun LK, Monk P, Tejwani S, Sonpavde G, Hwang C, Smith D, Jasti P, Dobson K, Dickow B, Heath EI, Semaan L, Cher ML, Fontana JA, Chinni S. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial. Jama Network Open. 4: e2034633. PMID 33496795 DOI: 10.1001/jamanetworkopen.2020.34633 |
0.49 |
|
| 2020 |
Powell IJ, Chinni SR, Reddy SS, Zaslavsky A, Gavande N. Pro-inflammatory cytokines and chemokines initiate multiple prostate cancer biologic pathways of cellular proliferation, heterogeneity and metastasis in a racially diverse population and underlie the genetic/biologic mechanism of racial disparity: Update. Urologic Oncology. PMID 32900629 DOI: 10.1016/J.Urolonc.2020.08.019 |
0.523 |
|
| 2019 |
Semaan L, Mander N, Cher ML, Chinni SR. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model. Bmc Cancer. 19: 972. PMID 31638934 DOI: 10.1186/S12885-019-6185-0 |
0.582 |
|
| 2018 |
Sbrissa D, Semaan L, Govindarajan B, Li Y, Caruthers NJ, Stemmer PM, Cher ML, Sethi S, Vaishampayan U, Shisheva A, Chinni SR. A novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cells. Oncogene. PMID 30111818 DOI: 10.1038/S41388-018-0448-0 |
0.601 |
|
| 2018 |
Vaishampayan UN, Heilbrun LK, Monk P, Tejwani S, Sonpavde G, Smith D, Jasti P, Dobson K, Heath EI, Cher ML, Chinni S, Fontana JA. Randomized trial of enzalutamide versus bicalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Journal of Clinical Oncology. 36: 190-190. DOI: 10.1200/Jco.2018.36.6_Suppl.190 |
0.512 |
|
| 2018 |
Chinni SR, Vaishampayan UN, Heilbrun LK, Semaan L, Smith D, Modi D, Monk P, Tejwani S, Sonpavde G, Dobson K, Dickow B, Heath E, Fontana J, Cher ML. Abstract LB-309: Evaluation of ERG as a biomarker of responsiveness in a randomized trial of enzalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-309 |
0.55 |
|
| 2018 |
Chinni SR, Semaan L, Cher M. Abstract 5422: TMPRSS2-ERG fusions confers efficacy of enzalutamide in an in vivo bone tumor growth model Cancer Research. 78: 5422-5422. DOI: 10.1158/1538-7445.Am2018-5422 |
0.519 |
|
| 2018 |
Vaishampayan UN, Heilbrun L, Monk P, Sonpavde G, Tejwani S, Heath EI, Fontana J, Chinni S. Randomized trial of androgen deprivation therapy (ADT) + enzalutamide (Arm A) versus ADT + bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC). Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy284.012 |
0.538 |
|
| 2016 |
Conley-LaComb MK, Semaan L, Singareddy R, Li Y, Heath EI, Kim S, Cher ML, Chinni SR. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis. Molecular Cancer. 15: 68. PMID 27809841 DOI: 10.1186/S12943-016-0552-0 |
0.595 |
|
| 2015 |
Powell K, Semaan L, Conley-LaComb MK, Asangani I, Wu YM, Ginsburg KB, Williams J, Squire JA, Maddipati KR, Cher ML, Chinni SR. ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2569-79. PMID 25754347 DOI: 10.1158/1078-0432.Ccr-14-2352 |
0.748 |
|
| 2015 |
Sakao K, Vyas AR, Chinni SR, Amjad AI, Parikh R, Singh SV. CXCR4 is a novel target of cancer chemopreventative isothiocyanates in prostate cancer cells. Cancer Prevention Research (Philadelphia, Pa.). 8: 365-74. PMID 25712054 DOI: 10.1158/1940-6207.Capr-14-0386 |
0.668 |
|
| 2015 |
Sbrissa D, Semaan L, Yanfeng L, Shisheva A, Chinni SR. Abstract 5162: Phosphatidylinositol 4-Kinase type IIIa (PI4KA) expression in prostate cancer Cancer Research. 75: 5162-5162. DOI: 10.1158/1538-7445.Am2015-5162 |
0.606 |
|
| 2015 |
Amjad AI, Sakao K, Vyas AR, Chinni SR, Parikh R, Singh SV. Abstract 1906: CXCR4 is a novel target of cancer chemopreventative isothiocyanates in prostate cancer cells Cancer Research. 75: 1906-1906. DOI: 10.1158/1538-7445.Am2015-1906 |
0.656 |
|
| 2015 |
Powell K, Semaan L, Conley-LaComb M, Asangani I, Wu Y, Williams J, Squire J, Maddipati K, Cher M, Chinni S. Mp37-02 Erg/Akr1C3/Ar Constitutes A Feed-Forward Loop For Ar Signaling In Prostate Cancer Cells The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1265 |
0.719 |
|
| 2014 |
Powell IJ, Dyson G, Chinni SR, Bollig-Fischer A. Considering race and the potential for ERG expression as a biomarker for prostate cancer. Personalized Medicine. 11: 409-412. PMID 25544850 DOI: 10.2217/Pme.14.26 |
0.554 |
|
| 2014 |
Wong D, Kandagatla P, Korz W, Chinni SR. Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis. Bmc Urology. 14: 12. PMID 24472670 DOI: 10.1186/1471-2490-14-12 |
0.596 |
|
| 2014 |
Powell KA, Semaan L, Maddipati KR, Conley-Lacomb K(, Li Y, Cher M, Chinni SR. Abstract 456: ERG regulation of intracrine androgen production and castration-resistant prostate cancer progression Cancer Research. 74: 456-456. DOI: 10.1158/1538-7445.Am2014-456 |
0.742 |
|
| 2013 |
Singareddy R, Semaan L, Conley-Lacomb MK, St John J, Powell K, Iyer M, Smith D, Heilbrun LK, Shi D, Sakr W, Cher ML, Chinni SR. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions. Molecular Cancer Research : McR. 11: 1349-61. PMID 23918819 DOI: 10.1158/1541-7786.Mcr-12-0705 |
0.728 |
|
| 2013 |
Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML, Chinni SR. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Molecular Cancer. 12: 85. PMID 23902739 DOI: 10.1186/1476-4598-12-85 |
0.654 |
|
| 2013 |
Conley-Lacomb K, Saliganan A, Chen YQ, Kim HC, Cher ML, Chinni SR. Abstract 4088: PTEN loss mediated Akt activation promotes prostate tumor growth via CXCL12/CXCR4 signaling. Cancer Research. 73: 4088-4088. DOI: 10.1158/1538-7445.Am2013-4088 |
0.705 |
|
| 2012 |
St John J, Powell K, Conley-Lacomb MK, Chinni SR. TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. Journal of Cancer Science & Therapy. 4: 94-101. PMID 23264855 DOI: 10.4172/1948-5956.1000119 |
0.721 |
|
| 2012 |
Conley-LaComb MK, Chen YQ, Kim HC, Cher ML, Chinni SR. Abstract C48: Regulation of expression of CXCL12 and its receptors CXCR4 and CXCR7 by PTEN in prostate cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Prca2012-C48 |
0.68 |
|
| 2011 |
Singareddy R, John JS, Chinni SR. Abstract 2159: Molecular characterization of ERG mediated CXCR4 transcriptional regulation Cancer Research. 71: 2159-2159. DOI: 10.1158/1538-7445.Am2011-2159 |
0.595 |
|
| 2010 |
Cai J, Kandagatla P, Singareddy R, Kropinski A, Sheng S, Cher ML, Chinni SR. Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells. Translational Oncology. 3: 195-203. PMID 20563261 DOI: 10.1593/Tlo.09328 |
0.621 |
|
| 2010 |
Aneja R, Miyagi T, Karna P, Ezell T, Shukla D, Vij Gupta M, Yates C, Chinni SR, Zhau H, Chung LW, Joshi HC. A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. European Journal of Cancer (Oxford, England : 1990). 46: 1668-78. PMID 20303260 DOI: 10.1016/J.Ejca.2010.02.017 |
0.591 |
|
| 2010 |
Chinni SR, Kandagatla P, Wong D, Korz W. Abstract 716: CXCR4 antagonist, CTCE-9908, inhibits PC-3 cell invasiveness and metastasis Cancer Research. 70: 716-716. DOI: 10.1158/1538-7445.Am10-716 |
0.564 |
|
| 2008 |
Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD, Cher ML. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Molecular Cancer Research : McR. 6: 446-57. PMID 18337451 DOI: 10.1158/1541-7786.Mcr-07-0117 |
0.65 |
|
| 2007 |
Bonfil RD, Chinni S, Fridman R, Kim HR, Cher ML. Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis. Urologic Oncology. 25: 407-11. PMID 17826661 DOI: 10.1016/J.Urolonc.2007.05.008 |
0.463 |
|
| 2007 |
Bonfil RD, Dong Z, Trindade Filho JC, Sabbota A, Osenkowski P, Nabha S, Yamamoto H, Chinni SR, Zhao H, Mobashery S, Vessella RL, Fridman R, Cher ML. Prostate cancer-associated membrane type 1-matrix metalloproteinase: A pivotal role in bone response and intraosseous tumor growth American Journal of Pathology. 170: 2100-2111. PMID 17525276 DOI: 10.2353/Ajpath.2007.060720 |
0.533 |
|
| 2007 |
Yamamoto H, Bonfil RD, Wiesner C, Nabha S, Dong Z, Meng H, Saliganan A, Sabbota A, Chinni SR, Cher ML. Quantitative assessment of small intraosseous prostate cancer burden in SCID mice using fluorescence imaging. The Prostate. 67: 107-14. PMID 17075820 DOI: 10.1002/Pros.20506 |
0.42 |
|
| 2007 |
Chinni SR, Yamamoto H, Dong Z, Sabbota A, Nabha S, Bonfil RD, Cher ML. 664: CXCL12/CXCR4 Trans-Activation of HER2 in Lipid Rafts of Prostate Cancer Cell Membranes Promotes Bone Metastasis The Journal of Urology. 177: 223-223. DOI: 10.1016/S0022-5347(18)30904-2 |
0.569 |
|
| 2006 |
Deng X, Bhagat S, Dong Z, Mullins C, Chinni SR, Cher M. Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel. European Journal of Cancer (Oxford, England : 1990). 42: 3267-73. PMID 16950615 DOI: 10.1016/J.Ejca.2006.07.003 |
0.654 |
|
| 2006 |
Bonfil RD, Sabbota A, Nabha S, Bernardo MM, Dong Z, Meng H, Yamamoto H, Chinni SR, Lim IT, Chang M, Filetti LC, Mobashery S, Cher ML, Fridman R. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. International Journal of Cancer. Journal International Du Cancer. 118: 2721-6. PMID 16381009 DOI: 10.1002/Ijc.21645 |
0.421 |
|
| 2006 |
Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, Cher ML. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. The Prostate. 66: 32-48. PMID 16114056 DOI: 10.1002/Pros.20318 |
0.569 |
|
| 2006 |
Bonfil RD, Dong Z, Trindade Filho JC, Zhao H, Ossenkowski P, Nabha S, Yamamoto H, Sabbota A, Chinni S, Vessella RL, Fridman R, Cher ML. 434: Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Promotes Tumor Growth and Bone Degradation in Prostate Cancer Bone Metastasis Journal of Urology. 175: 141-141. DOI: 10.1016/S0022-5347(18)32690-9 |
0.488 |
|
| 2005 |
Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Sloane BF, Sheng S, Fridman R, Cher ML. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. The American Journal of Pathology. 166: 1173-86. PMID 15793297 DOI: 10.1016/S0002-9440(10)62337-1 |
0.389 |
|
| 2005 |
Li Y, Chinni SR, Sarkar FH. Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Frontiers in Bioscience : a Journal and Virtual Library. 10: 236-43. PMID 15574364 DOI: 10.2741/1523 |
0.639 |
|
| 2005 |
Chinni SR, Sivalogan S, Dong Z, Filho JCT, Bonfil RD, Cher ML. 573: CXCL12 Chemokine-CXCR4 Receptor Interaction in Prostate Cancer Induces Akt Signaling, MMP-9 Expression, Motility and Invasion The Journal of Urology. 173: 156-157. DOI: 10.1016/S0022-5347(18)34813-4 |
0.571 |
|
| 2003 |
Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O. Soy isoflavones in the treatment of prostate cancer. Nutrition and Cancer. 47: 111-7. PMID 15087261 DOI: 10.1207/S15327914Nc4702_1 |
0.443 |
|
| 2003 |
Chinni SR, Alhasan SA, Multani AS, Pathak S, Sarkar FH. Pleotropic effects of genistein on MCF-7 breast cancer cells. International Journal of Molecular Medicine. 12: 29-34. PMID 12792805 |
0.398 |
|
| 2003 |
Chinni SR, Alhasan SA, Multani AS, Pathak S, Sarkar FH. Pleotropic effects of genistein on MCF-7 breast cancer cells. International Journal of Molecular Medicine. 12: 29-34. DOI: 10.3892/Ijmm.12.1.29 |
0.483 |
|
| 2002 |
Chinni SR, Sarkar FH. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 1228-36. PMID 11948137 |
0.304 |
|
| 2002 |
Glazyrin AL, Chinni S, Alhasan S, Adsay VN, Vaitkevicius VK, Sarkar FH. Molecular mechanism(s) of actinomycin-D induced sensitization of pancreatic cancer cells to CD95 mediated apoptosis. International Journal of Oncology. 20: 201-205. DOI: 10.3892/Ijo.20.1.201 |
0.377 |
|
| 2001 |
Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene. 20: 2927-36. PMID 11420705 DOI: 10.1038/Sj.Onc.1204365 |
0.587 |
|
| 2000 |
Rahman KM, Aranha O, Glazyrin A, Chinni SR, Sarkar FH. Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells. Oncogene. 19: 5764-71. PMID 11126363 DOI: 10.1038/Sj.Onc.1203959 |
0.373 |
|
| 2000 |
Li Y, Chinni SR, Senderowicz AM, Sarkar FH. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. International Journal of Oncology. 17: 755-9. PMID 10995888 DOI: 10.3892/Ijo.17.4.755 |
0.62 |
|
| Show low-probability matches. |